FDA to remove black box warnings on vaginal estrogen treatments amid growing backlash over outdated science

By bellecarter // 2025-07-21

Mastodon

Parler

Gab

Copy

The FDA is under increasing pressure to remove controversial black box warnings from vaginal estrogen treatments, as medical experts and patient advocates argue that these warnings deter women from accessing safe and effective relief for severe menopausal symptoms.
During a recent advisory session, physicians called for the FDA to reassess the warnings, claiming they misrepresent current scientific understanding and deny women essential care.
The black box warning stems from the Women's Health Initiative study, which linked systemic hormone replacement therapy to health risks. However, experts argue that these findings do not apply to localized vaginal estrogen treatments, which have minimal systemic absorption.
The warnings have led to tangible consequences, with many women avoiding estrogen therapy due to fear, despite its proven benefits in reducing urinary tract infections and alleviating painful intercourse.
The debate highlights systemic issues in women's healthcare, with FDA caution also affecting access to other treatments like testosterone. FDA Commissioner Marty Makary acknowledged past failures and pledged to reevaluate the warnings, aiming to align policy with modern science and restore autonomy to women facing menopause.

The Food and Drug Administration (FDA) is facing mounting pressure to remove controversial black box warnings from vaginal estrogen treatments, as medical experts and patient advocates argue that the "fear-inducing" labels are preventing millions of women from accessing safe and effective relief for debilitating menopausal symptoms. During a recent two-hour advisory session, physicians urged the agency to reassess the warning, saying it misrepresents modern science and denies women critical care. The black box warning traces back to the 2002-2003 Women's Health Initiative (WHI) study, which linked systemic hormone replacement therapy (HRT) to increased risks of stroke, blood clots and breast cancer in older women. However, experts now argue that the study's conclusions, drawn from oral equine estrogen pills, should not apply to localized vaginal estrogen treatments, which deliver minimal systemic absorption. Dr. James A. Simon, a professor at George Washington University, emphasized that vaginal estrogen does not enter the bloodstream in detectable amounts. "When you measure estrogen from these low-dose vaginal products, you cannot find it in the blood," he said. Nevertheless, the stigma persists, discouraging both patients and providers from considering the therapy, despite its proven benefits in reducing recurrent urinary tract infections and alleviating painful intercourse. The warnings have had tangible consequences. Up to half of postmenopausal women suffer from vaginal atrophy, which is the thinning and dryness caused by plummeting estrogen levels, leading to discomfort, recurrent infections and sexual dysfunction. Yet many avoid estrogen therapy due to fear. Dr. Heather Hirsch, a menopausal specialist, described patients who abandoned treatment, opting instead for chronic pain or abstinence. "Women are choosing to suffer rather than risk theoretical harms," she told the FDA panel. "We are doing harm in the name of 'do no harm.'" Even guidelines from the American Urological Association endorse vaginal estrogen for urinary and sexual health, yet confusion over the black box label persists. Dr. Rachel Rubin, a urologist and sexual health expert, called the warning "factually incorrect," citing zero evidence linking vaginal estrogen to the risks listed, including breast cancer and dementia.

Broader implications for women's healthcare

The debate reflects wider issues in how women's health concerns are addressed. Dr. Kelly Casperson, a urologist, noted that FDA caution has also hampered access to testosterone for women, despite its benefits for libido, bone health and nerve function. "The legacy of the WHI backlash has frozen progress," she said. FDA Commissioner Dr. Marty Makary acknowledged systemic failures, pledging to reevaluate the black box warning and improve transparency. "Women's health issues have been sidelined for too long," he said. (Related: Plant-based diet can reduce hot flashes in menopausal women, study finds.) The agency's decision could mark a pivotal shift – one that aligns policy with modern science and restores autonomy to millions navigating menopause. For now, advocates hope urgency prevails over inertia. As Rubin put it: "Women deserve the truth, not outdated myths." With menopause affecting roughly 50 million U.S. women at any given time, the FDA's reconsideration of vaginal estrogen warnings could redefine care for a generation. As science evolves, so too must policy, ensuring patients aren't deprived of relief based on decades-old fears. The question remains: Will regulators act swiftly, or will women continue paying the price for outdated dogma? Watch the video below that talks about natural treatment options for menopause. This video is from the Holistic Herbalist channel on Brighteon.com.

CITIZENS NEWS

Broader implications for women's healthcare

More related stories:

Sources include: